Skip to main content
SpringerLink
Log in

Novità nella terapia medica della malattia di Cushing

Proposto da Renato Cozzi

  • Published:
L’Endocrinologo Aims and scope

Riassunto

La malattia di Cushing è una patologia per la quale, a differenza di altri tumori ipofisari, non esiste una terapia farmacologica universalmente accettata ed efficace. Il farmaco più utilizzato è il chetoconazolo, un inibitore della steroidogenesi, dato che i farmaci che agiscono direttamente sui corticotropi tumorali hanno ottenuto solo di recente dei risultati promettenti. La loro efficacia è peraltro variabile ed è spesso necessario fare diversi tentativi terapeutici con farmaci che agiscono a livello ipofisario o surrenalico, da soli o in associazione.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Bibliografia

  1. Cavagnini F, Pecori Giraldi F 2002 Terapia della malattia di Cushing. L’Endocrinologo 3: 166–175.

    Google Scholar 

  2. Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T 2008 Ketoconazole revisited: a preoperative or postoperative treatment in Cushing’s disease. Eur J Endocrinol 158: 91–99.

    Article  PubMed  CAS  Google Scholar 

  3. Valassi E, Crespo I, Gich I, Rodriguez J, Webb SM 2012 A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing’s syndrome. Clin Endocrinol (Oxf) 77: 735–742.

    Article  CAS  Google Scholar 

  4. Feelders RA, De Bruin C, Pereira AM et al 2010 Pasireotide alone or with cabergoline and ketoconazole in Cushing’s disease. N Engl J Med 362: 1846–1847.

    Article  PubMed  CAS  Google Scholar 

  5. Kamenicky P, Droumaguet C, Salenave S et al 2011 Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing’s syndrome. J Clin Endocrinol Metab 96: 2796–2804.

    Article  PubMed  CAS  Google Scholar 

  6. Chan LF, Vaidya M, Westphal B et al 2011 Use of intravenous etomidate to control acute psychosis induced by the hypercortisolemia in severe paediatric Cushing’s disease. Horm Res Ped 75: 441–446.

    Article  CAS  Google Scholar 

  7. Tolis G, Karalis C, Stratakis CA 1990 Efficacy of dopaminergic agents on ACTH-dependent hypercortisolemia. In: Lüdecke DK, Chrousos GP, Tolis G, eds. ACTH, Cushing’s Syndrome and Other Hypercortisolemic States. New York: Raven Press, 239–243.

    Google Scholar 

  8. Pivonello R, De Martino MC, Cappabianca P et al 2009 The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94: 223–230.

    Article  PubMed  CAS  Google Scholar 

  9. Godbout A, Manavela M, Danilowicz K et al 2010 Cabergoline in the long-term treatment of Cushing’s disease. Eur J Endocrinol 163: 709–716.

    Article  PubMed  CAS  Google Scholar 

  10. Colao A, Petersenn S, Newell-Price J et al 2012 A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med 366: 914–924.

    Article  PubMed  CAS  Google Scholar 

  11. Fiorentino C, Motta C, Wolosinska DT et al 2011 SOM230 in Cushing’s disease complicated by poorly controlled diabetes mellitus. J Endocrinol Invest 34: 731–732.

    Article  PubMed  CAS  Google Scholar 

  12. Pecori Giraldi F, Ambrogio AG, Andrioli M et al 2012 Efficacy oflong-term treatment with retinoic acid in patients with Cushing’s disease. J Clin Endocrinol Metab 97: 3577–3583.

    Article  PubMed  CAS  Google Scholar 

  13. McCormack AI, Wass JAH, Grossman AB 2011 Aggressive pituitary tumors: the role of temozolomide in the assessment of MGMT status. Eur J Clin Invest 41: 1133–1148.

    Article  PubMed  CAS  Google Scholar 

  14. Fleseriu M, Biller BMK, Findling JW et al 2012 Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome. J Clin Endocrinol Metab 97: 2039–2049.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratorio di Ricerche Neuroendocrinologiche, Istituto Auxologico Italiano IRCCS, Milan, Italia

    Martina De Martin

  2. Dipartimento di Scienze Cliniche e della Comunità, Università degli Studi di Milano, Istituto Auxologico Italiano IRCCS, Laboratorio di Ricerche Neuroendocrinologiche, Piazzale Brescia 20, 20149, Milano, Italia

    Francesca Pecori Giraldi

Authors
  1. Martina De Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesca Pecori Giraldi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesca Pecori Giraldi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Martin, M., Giraldi, F.P. Novità nella terapia medica della malattia di Cushing. L’Endocrinologo 13, 254–258 (2012). https://doi.org/10.1007/BF03346013

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03346013

Search

Navigation